

Applicants: Peter S. Linsley et al.
U.S. Serial No.: 08/219,200
Filed: March 29, 1994
Page 2

Please amend the subject application as follows.

In the Claims:

Please cancel claims 37, 38 and 39 without prejudice to applicants' right to pursue protection for the subject matter defined by these claims if applicants determine to do so in a continuation or divisional application in the future.

Please amend claim 1, 19, 40, and 78 as follows.

--1. (X4 Amended) A method for inhibiting T cell proliferation comprising contacting CD28 positive T cells with B7 antigen [or an anti-CD28 monoclonal antibody] so as to bind the CD28 receptor on the CD28 positive T cells with B7 antigen [or an anti-CD28 monoclonal antibody] and thereby inhibiting T cell proliferation.

--19. (X5 Amended) A method of inhibiting [CD28 positive] T cell-dependent B cell response [proliferation] comprising reacting B7 positive cells with an [monoclonal antibody designated BB-1 or a F(ab)₂ fragment thereof or the] exogenous CD28Ig fusion protein and thereby blocking B7-T cell interaction and inhibiting [CD28 positive] T cell-dependent B cell response [proliferation].--

--40. (X2 Amended) The method of claim [39] 19, wherein [said fusion protein is] the CD28Ig fusion protein [corresponding] corresponds to the amino acid sequence encoded by coding region of dna sequence encoding

Applicants: Peter S. Linsley et al.
U.S. Serial No.: 08/219,200
Filed: March 29, 1994
Page 3

(P)
cd28ig containing plasmid or ecoli having plasmid the
ecoli designated DNA having ATCC No. 68628-- ecoli
containing plasmid having... or

(T)
--78. (Amended) A method of inhibiting [CD28 positive] T cell-dependent B cell response [activation] comprising reacting B7 positive cells with a CD28 antigen so as to bind the B7 positive cells with [the] an exogenous CD28 antigen thereby inhibiting T cell-dependent B cell response [activation].

REMARKS

Claims 1, 3, 5-10, 18-19, 28-32, 37-42, and 78 were pending. Claims 37, 38 and 39 have been canceled hereinabove. Claims 1, 19, 40, and 78 have been amended hereinabove. Accordingly, only claims 1, 3, 5-8, 18, 19, 40-42, and 78 are pending and being examined.

Support for the changes to claims 19 and 78 may be found in the specification as originally filed at page 22, lines 26-27, page 48, line 22, and pages 12-27. Support for the changes to claims 1 and 40 may be found in the specification as originally filed at page 48, line 22, and pages 12-27. The changes to the claims do not involve new matter and applicants respectfully request entry of them.